Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Atrial Fibrillation in Cancer Patients: Who is at Risk?

https://doi.org/10.20996/1819-6446-2021-12-03

Full Text:

Abstract

Cancer is the second leading cause of mortality in the world, second only to cardiovascular diseases. Simultaneously cancer mortality has been steadily decreasing due to the development  of new chemotherapy and targeted  drugs  and the improvement  of existing  treatment protocols.  Improving the prognosis of treatment of cancer patients leads to an unexpected  result - more patients are faced with side effects of cancer treatment. Cardiotoxicity, including  arrhythmia, has  become  a significant  factor  to reduce  the effectiveness  of cancer  patient’s  treatment.  Atrial  fibrillation  is frequent  and persistent a rhythm disorder, affecting  all categories  of patients, especially the elderly. An association  between these two conditions  can be expected, considering the fact that in old age the prevalence of malignant neoplasms  and comorbid pathology predisposing to the onset of AF is high. Therefore, AF may be an additional  factor negatively  influencing the prognosis and treatment tactics in patients with malignant neoplasms. A comprehensive search was conducted  using the keywords  “cancer”, “atrial fibrillation” and “cardiotoxicity” using the PubMed,  Scopus and Cohrane  databases. We reviewed publications having the relationship between AF and cancer. The literature review considered 61 publications on the prevalence of AF in cancer patients, classification, mechanisms of development, the effect of anticancer drugs and other treatment methods on this group of patients. Analyzed articles include clinical guidelines, consensus  expert opinions,  systematic  reviews,  meta-analyzes, and previously  published  reviews of the literature. The problem of cardiotoxic  complications diagnostics is evaluated separately,  incl. arrhythmias, and their monitoring in cancer patients. Therefore, the direction of medicine named "Cardio-oncology" comes to the fore. Interdisciplinary interaction will allow identify cardiotoxic  manifestations at the subclinical stage and optimize anticancer treatment.

About the Authors

Yu. A. Vasyuk
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Yuriy A. Vasyuk.

Moscow.

eLibrary SPIN 2265-5331



E. Yu. Shupenina
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Yelena Y. Shupenina.

Moscow.

eLibrary SPIN 2090-9938



D. A. Vyzhigin
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Dmitriy A. Vyzhigin.

Moscow.

eLibrary SPIN 9175-7217



E. O. Novosel
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Yevgeniya O. Novosel.

Moscow.

eLibrary SPIN 8536-7910



K. V. Gallinger
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Karina V. Gallinger.

Moscow.

eLibrary SPIN 5820-5967



References

1. Globocan 2020: All cancers. WHO, International Agency for Research on Cancer [cited 2021 April 30]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf.

2. Cancer tomorrow: Estimated number of new cases from 2020 to 2040, Both sexes, age. WHO, International Agency for Research on Cancer [0-85+] [cited 2021 April 30]. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/bubbles?sexes=0&mode=population&types=0.

3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7‐33. DOI:10.3322/caac.21654.

4. Kaprin AD, Starinskiy VV, Shakhzadova AO, ed. The state of cancer care for the population of Russia in 2019. Moscow: LLC "Helvetika"; 2020 (In Russ.).

5. Vasyuk YA, Yushchuk EN, Nesvetov VV. Cardiooncology: a new challenge of our time. Cardiovascular complications of antitumor treatment. Moscow: KlinMedConsulting; 2019 (In Russ.).

6. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology. 2015;12(9):547-58. DOI:10.1038/nrcardio.2015.65.

7. Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.

8. Vasyuk YuA, Shupenina EYu, Novosel YeO, Agapov IS. Cardiac arrhythmias and conduction disorders as manifestations of cardiotoxicity of anticancer treatment - myth or reality? Siberian Medical Journal. 2020;35(1):13-21 (In Russ.). DOI:10.29001/2073-8552-2020-35-1-13-21.

9. Ostroumova OD, Chernyayeva MS, Kochetkov AI, et al. Drug-induced atrial fibrillation associated with the use of anticancer drugs. Bezopasnost' i Risk Farmakoterapii. 2020;8(4):178-90 (In Russ.). DOI:10.30895/2312-7821-2020-8-4.

10. Asteggiano R, Norbiato C, Marengo S, Parrini I. Cancer and arrhythmias. e-Journal of Cardiology Practice. 2021;19(21) [cited 2021 April 30]. Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/cancer-and-arrhythmias.

11. Bailey CC, Betts RH. Cardiac arrhythmias following pneumonectomy. N Engl J Med. 1943;229:356-9. DOI:10.1056/NEJM194308262290902.

12. Alexandre J, Molsehi JJ, Bersell KR, et al. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018;189:89-103. DOI:10.1016/j.pharmthera.2018.04.009.

13. Yuan M, Zhang Z, Tse G, et al. Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiol Res Pract. 2019;2019:8985273. DOI:10.1155/2019/8985273.

14. Kattelus H, Kesäniemi YA, Huikuri H, Ukkola O. Cancer increases the risk of atrial fibrillation during longterm follow-up (OPERA study). PLOS ONE, 2018;13(10):e0205454. DOI:10.1371/journal.pone.0205454.

15. Jakobsen CB, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12year follow up study. BMC Cancer. 2018;19(1):1105. DOI:10.1186/s12885-019-6314-9.

16. Lardaro T, Self WH, Barrett TW. Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer. The American Journal of Emergency Medicine, 2015; 33(10), 1483-1488. DOI:10.1016/j.ajem.2015.07.033.

17. Sorigue M, Miljkovic MD. Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists. Journal of Oncology Practice, 2019; 15 (12), 641-650. DOI:10.1200/jop.18.00592.

18. Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in Patients With Cancer. Journal of the American College of Cardiology, 2017; 70 (8), 926-938. DOI:10.1016/j.jacc.2017.06.047.

19. Khan MA, Ahmed F, Neyses L, Mamas MA. Atrial fibrillation in heart failure: the sword of Damocles revisited. World J Cardiol. 2013;5(7):215-27. DOI:10.4330/wjc.v5.i7.215.

20. Guo Y, Tian Y, Wang H, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109-19. DOI:10.1378/chest.14-0321.

21. Yang X, Li X, Yuan M, et al. Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms. Front Pharmacol. 2018;9:1058. DOI:10.3389/fphar.2018.01058.

22. Voigt N, Heijman J, Wang Q, et al. Cellular and Molecular Mechanisms of Atrial Arrhythmogenesis in Patients With Paroxysmal Atrial Fibrillation. Circulation. 2013;129(2):145-56. DOI:10.1161/circulationaha.113.006641.

23. Nattel S, Burstein B, Dobrev D. Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circulation: Arrhythmia and Electrophysiology, 2008; 1 (1), 62-73. DOI:10.1161/circep.107.754564.

24. Neef S, Dybkova N, Sossalla S, et al. CaMKII-Dependent Diastolic SR Ca2+ Leak and Elevated Diastolic Ca2+ Levels in Right Atrial Myocardium of Patients With Atrial Fibrillation. Circ Res. 2010;106(6):1134-44. DOI:10.1161/circresaha.109.203836.

25. Yang X, Li Y, Li Y, et al. Oxidative Stress-Mediated Atherosclerosis: Mechanisms and Therapies. Front Physiol. 2017;8:600. DOI:10.3389/fphys.2017.00600.

26. Gen W, Tani M, Takeshita J, et al. Mechanisms of Ca 2+ overload induced by extracellular H2O2 in quiescent isolated rat cardiomyocytes. Basic Res Cardiol. 2001;96(6):623-9. DOI:10.1007/s003950170014.

27. Chu G, Versteeg HH, Verschoor AJ, et al. Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. Blood Rev. 2019;35:59-67. DOI:10.1016/j.blre.2019.03.005.

28. Znahd Y, Wang YT, Shan ZL, et al. Role of inflammation in the initiation and maintenance of atrial fibrillation and the protective effect of atorvastatin in a goat model of aseptic pericarditis. Molecular Medicine Reports. 2014;11(4):2615-23. DOI:10.3892/mmr.2014.3116.

29. Guzzetti S. Systemic Inflammation, Atrial Fibrillation, and Cancer. Circulation. 2002;106(9):e40. DOI:10.1161/01.cir.0000028399.42411.13.

30. Schieppati F, Russo D, Falanga A. Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. Semin Thromb Hemost. 2015;41(7):756-64. DOI:10.1055/s-0035-1564040.

31. Zamorano JL, Lancellotti P, Muñoz DR, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801. DOI:10.1093/eurheartj/ehw211.

32. Roselli EE, Murthy SC, Rice TW, et al. Atrial fibrillation complicating lung cancer resection. J Thorac Cardiovasc Surgю 2005;130(2):438-44. DOI:10.1016/j.jtcvs.2005.02.010.

33. Siu CW, Tung HM, Chu KW, et al. Prevalence and Predictors of New-Onset Atrial Fibrillation After Elective Surgery for Colorectal Cancer. Pacing Clin Electrophysiol. 2005;28(s1):120-3. DOI:10.1111/j.1540-8159.2005.00024.

34. Ojima T, Iwahashi M, Nakamori M, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2013;44(5):839-47. DOI:10.1007/s00595-013-0616-3.

35. Schizas D, Kosmopoulos M, Giannopoulos S, et al. Meta-analysis of risk factors and complications associated with atrial fibrillation after oesophagectomy Br J Surg. 2019;106(5):534-47. DOI:10.1002/bjs.11128.

36. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2013;21(1):15-25. DOI:10.1038/cdd.2013.67.

37. Amioka M, Sairaku A, Ochi T, et al. Prognostic Significance of New-Onset Atrial Fibrillation in Patients With Non-Hodgkin’s Lymphoma Treated With Anthracyclines. Am J Cardiol. 2016;118(9):1386-89. DOI:10.1016/j.amjcard.2016.07.049.

38. Ma H, Jones KR, Guo R, et al. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: Role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol. 2010;37(4):460-5. DOI:10.1111/j.1440-1681.2009.05323.x.

39. Lara PN. The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial. Clin Cancer Res. 2005;11(12):4444-50. DOI:10.1158/1078-0432.ccr-04-2602.

40. Richards WG, Zellos L, Bueno R, et al. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma. J Clin Oncol. 2006;24 (10):1561-7. DOI:10.1200/jco.2005.04.6813.

41. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405-11. DOI:10.1016/j.jtcvs.2009.02.046.

42. Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleuralpneumonectomyand intracavitary intraoperative hyperthermic cisplatin with amifostinecytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453-8. DOI:10.1016/j.jtcvs.2008.07.055.

43. ElZarrad MK, Mukhopadhyay P, Mohan N, et al. Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice. PLoS ONE. 2013;8(11):e79543. DOI:10.1371/journal.pone.0079543.

44. Yuan M, Tse G, Zhang Z, et al. The incidence of atrial fibrillation with Trastuzumab treatment: a systematic review and meta-analysis. Cardiovasc Ther. 2018;36(6):e12475. DOI:10.1111/1755-5922.12475.

45. Aziz SA, Tramboo NA, Mohi-ud-Din K, et al. Supraventricular arrhythmia: A complication of 5-fluorouracil therapy. Clin Oncol (R Coll Radiol). 1998;10(6):377-8. DOI:10.1016/s0936-6555(98)80033-2.

46. Meydan N. Cardiotoxicity of de Gramont’s Regimen: Incidence, Clinical Characteristics and Long-term Follow-up. Jpn J Clin Oncol. 2005;35(5):265-70. DOI:10.1093/jjco/hyi071.

47. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;(15):117-30.

48. Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori. 2004;90(3):285-8.

49. Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2003;95(10):977-81.

50. Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. Lung Cancer. 2001;31(2-3):277-84. DOI:10.1016/s0169-5002(00)00194-x.

51. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. J Natl Cancer Inst. 2007;99(9):727-37. DOI:10.1093/jnci/djk154.

52. Issac TT, Dokainish H, Lakkis NM. Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation. J Am Coll Cardiol. 2007;50(21):2021-8. DOI:10.1016/j.jacc.2007.06.054.

53. Passalia C, Minetto P, Arboscello E, et al. Cardiovascular adverse events complicating the administration of rituximab: Report of two cases. Tumori. 2013;99(6):288e-92e. DOI:10.1700/1390.15471.

54. Foran JM, Rohatiner AZS, Cunningham D, et al. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. J Clin Oncol. 2000;18(2):317-7. DOI:10.1200/jco.2000.18.2.317

55. Petrini I, Lencioni M, Ricasoli M, et al. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;69(3):773-80. DOI:10.1007/s00280-011-1753-2.

56. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-37. DOI:10.1056/nejmoa1509388.

57. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-11. DOI:10.1016/s1470-2045(15)00465-9.

58. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-8. DOI:10.1016/s0140-6736(15)00667-4.

59. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways. Am J Clin Oncol. 2016;39(1):98-106. DOI:10.1097/coc.0000000000000239.

60. Lee HC, Huang KTL, Wang XL, et al. Autoantibodies and Cardiac Arrhythmias. Heart Rhythm. 2011;8(11):1788-95. DOI:10.1016/j.hrthm.2011.06.032.

61. Mery B, Guichard JB, Guy JB, et al. Atrial fibrillation in cancer patients: Hindsight, insight and foresight. Int J Cardiol. 2017;240:196-202. DOI:10.1016/j.ijcard.2017.03.132.

62. Armenian SH, Lacchetti C, Barac, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911. DOI:10.1200/jco.2016.70.5400.

63. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020,31(2):171-90. DOI:10.1016/j.annonc.2019.10.023.

64. Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020;9(18):e018403. DOI:10.1161/JAHA.120.018403.


Review

For citation:


Vasyuk Yu.A., Shupenina E.Yu., Vyzhigin D.A., Novosel E.O., Gallinger K.V. Atrial Fibrillation in Cancer Patients: Who is at Risk? Rational Pharmacotherapy in Cardiology. 2021;17(6):900-907. (In Russ.) https://doi.org/10.20996/1819-6446-2021-12-03

Views: 77


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)